DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03846219 (ClinicalTrials.gov)	January 28, 2019	21/1/2019	MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)	Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial Assessing the Effect of IMU-838 on Disease Activity, as Measured by Magnetic Resonance Imaging (MRI), as Well as Safety and Tolerability in Patients With Relapsing-remitting Multiple Sclerosis (RRMS)	Relapsing-Remitting Multiple Sclerosis (RRMS)	Drug: IMU-838 (30 mg/day);Drug: IMU-838 (45 mg/day);Drug: Placebo	Immunic AG	NULL	Active, not recruiting	18 Years	55 Years	All	210	Phase 2	Bulgaria;Poland;Romania;Ukraine

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03846219
(ClinicalTrials.gov)

January 28, 2019

21/1/2019

MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)

Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial Assessing the Effect of IMU-838 on Disease Activity, as Measured by Magnetic Resonance Imaging (MRI), as Well as Safety and Tolerability in Patients With Relapsing-remitting Multiple Sclerosis (RRMS)

Relapsing-Remitting Multiple Sclerosis (RRMS)

Drug: IMU-838 (30 mg/day);Drug: IMU-838 (45 mg/day);Drug: Placebo

Immunic AG

NULL

Active, not recruiting

18 Years

55 Years

All

210

Phase 2

Bulgaria;Poland;Romania;Ukraine